Stockscreener 앱 받기
10.48
3.76%
0.38
시간 외 거래:
10.48
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Keros Therapeutics Secures $20 Million Milestone Payment From Takeda - sekbernews.id
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Wall Street Zen - marketbeat.com
Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity? - Yahoo Finance
Understanding Momentum Shifts in (KROS) - Stock Traders Daily
Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP - marketbeat.com
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.83, Implies 86% Upside - TradingView
BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20 - marketscreener.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - marketbeat.com
Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen - marketbeat.com
Renaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS - marketbeat.com
Keros Therapeutics, Inc. (KROS) Stock Analysis: Unveiling a 90.92% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment - qz.com
FY2026 EPS Estimate for Keros Therapeutics Raised by Analyst - MarketBeat
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus - The Globe and Mail
KROS Maintained by Wells Fargo -- Price Target Lowered to $18.00 - GuruFocus
Leerink Partners Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23 - Moomoo
Keros Therapeutics (NASDAQ:KROS) Price Target Lowered to $23.00 at Leerink Partners - marketbeat.com
Keros Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
KEROS THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $23 FROM $30 - Bitget
Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS - MarketBeat
Keros Therapeutics 2026: Revenue $0 EPS ($1.45) — 10-Q Summary - TradingView
Keros Therapeutics posts $28.7 million second quarter net loss - Quiver Quantitative
KROS: Reduced net loss and strong cash position support ongoing clinical progress into 2028 - TradingView
Keros Therapeutics Reports Second Quarter 2026 Financial Results - GlobeNewswire
Avoiding Lag: Real-Time Signals in (KROS) Movement - Stock Traders Daily
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026? - qz.com
Keros Therapeutics, Inc. (KROS) Stock Analysis: Navigating a 113.63% Potential Upside in Biotechnology - DirectorsTalk Interviews
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Zacks Research - MarketBeat
Keros Therapeutics to Receive $20M Development Milestone Payment From Takeda - Moomoo
Keros Therapeutics Earns Milestone Payment for Elritercept Trial - TipRanks
Keros Therapeutics to Receive $20M Milestone After First ELRiSE MDS Patient Dosed - TradingView
Keros Therapeutics (KROS) Holds Near Support After Modest GainLinear Regression - dars.gov.et
New Strong Sell Stocks for July 30th - theglobeandmail.com
Keros Therapeutics (KROS) Projected to Post Earnings on Wednesday - marketbeat.com
Keros Therapeutics Inc (KROS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Keros Therapeutics Inc (KROS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Keros Therapeutics Inc (KROS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Keros Therapeutics Inc (KROS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
KROS|Keros Therapeutics Inc|Price:9.860|Chg%:-0.350 - TradingKey
Keros Therapeutics Inc (KROS) Cash Flow - TradingKey
Keros Therapeutics, Inc. Revenue Breakdown – NASDAQ:KROS - TradingView
Keros Therapeutics Inc (KROS) Institutional Confidence - TradingKey
Keros Therapeutics Inc (KROS) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
KROS|Keros Therapeutics Inc|Price:10.060|Chg%:-0.080 - TradingKey
Keros TherapeuticsKeith Regnante Resigns As CFO - TradingView
Keros Therapeutics Announces CFO Resignation and Interim Successor - TipRanks
Keros Therapeutics (NASDAQ: KROS) names interim finance and accounting head - Stock Titan
Discipline and Rules-Based Execution in KROS Response - Stock Traders Daily
Keros Therapeutics CFO Keith Regnante resigns effective Aug. 3 - scanx.trade
Keros Therapeutics (KROS) Holds Steady Near Support LevelUp Down Volume - dars.gov.et
Keros Therapeutics (KROS) director adds 1,000 shares under 10b5-1 plan - Stock Titan
BlackRock Portfolio Management (KROS) discloses 5.7% ownership in Keros Therapeutics - Stock Titan
Insiders Sold Keros Therapeutics Prematurely At US$15.15 With Stock Trading Higher - simplywall.st
Nurix Therapeutics (NRIX) soars 16.4%: Is further upside left in the stock? - MSN
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
KROS Q1 2026 Earnings: Wider-than-Expected Loss as Clinical Progress ContinuesEPS Growth Rate - dars.gov.et
KROS Q1 2026 Earnings: EPS Miss of 15.98% as Clinical-Stage Biotech Reports Wider-Than-Expected LossProfit Announcement - dars.gov.et
Keros Therapeutics | DEFA14A: Others - Moomoo
Form 4 Keros Therapeutics Inc For: 6 July By Investing.com - Investing.com Nigeria
Keros Therapeutics (KROS) grants director Anne Prener RSUs and stock options - Stock Titan
1.80%
1.77%
자본화:
|
볼륨(24시간):